Corbus Pharmaceuticals Holdings, Inc.s in-depth stock price analysis indicates that the stock price has rallied 2.16% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 65.5% . Looking at the past 52 week period, the stock price is up at 512.07% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Corbus Pharmaceuticals Holdings, Inc. has a positive value of 366.85 compared to overall market. Stocks of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) rallied by 3.65% during the past week but lost 5.33% on a 4-week basis. The company has outperformed the S&P 500 by 2.81% in the past week but underperformed the index by 7.03% in the last 4 weeks.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) : On Friday heightened volatility was witnessed in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) which led to swings in the share price. The stock opened for trading at $6.35 and hit $7.55 on the upside , eventually ending the session at $7.1, with a gain of 13.6% or 0.85 points. The heightened volatility saw the trading volume jump to 3,499,802 shares. The 52-week high of the share price is $10.78 and the company has a market cap of $316 million. The 52-week low of the share price is at $1.01 .
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by JMP Securities on Nov 15, 2016 to Mkt Outperform, Raises Price Target to $ 20 from a previous price target of $9 .
Company has reported several Insider transactions to the SEC, on Jan 20, 2017, Yuval Cohen (CEO) purchased 1,340 shares at 7.64 per share price.On Dec 2, 2016, Sean F. Moran (CFO) purchased 1,500 shares at 7.20 per share price.On Dec 1, 2016, Barbara White (Chief Medical Officer) purchased 1,000 shares at 7.75 per share price.
Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics to treat life threatening (orphan) inflammatory-fibrotic diseases. The Companys lead product is Resunab (TM), an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and scleroderma. Corbus Pharmaceuticals Holdings, Inc. is based in Norwood, Massachusetts.